logo









Adamas pharmaceuticals

Adamas pharmaceuticals



Adamas Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes therapies for chronic neurologic disorders, including its approved product GOCOVRI for treating levodopa-induced dyskinesia in Parkinson's disease patients.
Sign up today to get real-time market insights on Adamas pharmaceuticals and hundreds of other pre-IPO companies



Adamas pharmaceuticals Overview

Emeryville, CA, United States
2000
Biotech



Adamas pharmaceuticals Live Market Data

$00000000
$00000000




Adamas pharmaceuticals Funding Rounds



RoundDateAmount RaisedValuationInvestorsSources
Merger/Acquisition11/24/2021
IPO4/10/2014
Later Stage1/9/2014
Series D8/19/2009
Series C17/27/2007
Series C
6/27/2006




Adamas pharmaceuticals Investors



InvestorInvestment RoundsLead PartnerInitial InvestmentOther Notable Investments
DAG VenturesSeries DSeries D (2009-08-19)
EDBISeries DSeries D (2009-08-19)
Ontario Teachers' Pension PlanSeries DSeries D (2009-08-19)




Adamas pharmaceuticals 409a Valuations



DatePrice per shareEst. ValuationFilling
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Sign up to access Adamas pharmaceuticals data




Adamas pharmaceuticals Filings



TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign up to access Adamas pharmaceuticals data










DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.